Results From Positive Phase 1 Study of NovaDigm Therapeutics ’ NDV-3 Vaccine for Candida and Staph Infections Published in Vaccine
12/13/2012 10:12:39 AM
More...
|
Pfizer Inc. (PFE), GlaxoSmithKline (GSK) and NovaDigm Therapeutics ' Vaccine for Staph More Lethal Than Skin Cancer Tested
9/17/2012 8:01:15 AM
More...
|
NovaDigm Therapeutics Presents Positive Safety and Immunogenicity Data in a Second Phase 1 Study for NDV-3 Vaccine
5/7/2012 9:52:42 AM
More...
|
NovaDigm Therapeutics Presents Positive Preclinical Data in Vulvovaginal Candidiasis for NDV-3 Vaccine
9/19/2011 7:16:53 AM
More...
|
NovaDigm Therapeutics to Present Positive Clinical and Preclinical Data for NDV-3 Vaccine at ICAAC
9/12/2011 10:20:04 AM
More...
|